To observe the efficacy and safety of bifidobacterium triple viable capsule in patients with type Ⅲ prostatitis.

Patients with type Ⅲ prostatitis in the hospital were retrospectively selected and divided into treatment group and control group. The two groups of patients both took sertraline tablets 0.05 g, once daily. Patients in control group were given oral administration of 0.2 mg of tamsulosin sustained release capsule once a day, while patients in treatment group received oral administration of 0.42 g of bifidobacterium triple viable capsule twice a day on the basis of control group. Both groups were treated for 4 weeks. The efficacy, clinical symptoms scores, urodynamic parameters and inflammatory factors were compared between the two groups, and the safety was evaluated.

A total of 200 patients were enrolled, including 97 cases in control group and 103 cases in treatment group. After 4 weeks of treatment, the total effective rate in treatment group was 88.35% (91 cases/103 cases), which was statistical significant higher than 79.38% (77cases/97 cases) in control group (P>0.05). After treatment, the scores of the pain domain of the national institutes of health chronic prostatitis symptom index (NIH-CPSI) in treatment group and control group were (4.37±1.42) and (5.04±1.56) point, respectively; the self-rating depression scale (SDS) scores were (38.20±5.38) and (40.63±5.54) point, respectively; the levels of interleukin-6 (IL-6) were (5.93±1.08) and (6.30±1.27) pg·mL^-1, respectively; the levels of interleukin-10 (IL-10) were (6.21±1.37) and (6.62±1.49) pg·mL^-1, respectively; and the levels of cyclooxygenase-2 (COX-2) were (9.46±2.66) and (10.26±2.02) ng·mL^-1, respectively. There were statistical significant differences in the above indicators between treatment and control group (all P<0.05). The main adverse drug reactions in treatment group included dizziness, nausea and vomiting, and diarrhea, whereas dizziness and diarrhea occurred in control group. The overall incidence of adverse drug reactions was 4.85% (5 cases/103 cases) in treatment group and 2.06% (2 cases/97 cases) in control group, with no statistically significant difference between the two groups (P>0.05).

Bifidobacterium triple viable capsule in the treatment of type Ⅲ prostatitis can improve the pain symptom and depression, and regulate the levels of inflammatory factors, and it has good safety.